Tesamorelin

Product Name: Tesamorelin

Cas No: 218949-48-5

Molar Mass: 5135.86

Chemical Formula: C221H366N72O67S

Synonyms: Egrifta, TH 9507

Storage: Store at -20°C

Sequence: YADAIFTNSY RKVLGQLSAR KLLQDIMSRQ QGESNQERGA RARL

Target Indicators: GHRH

Purity: 98%

Application: Tesamorelin (CAS: 218949-48-5) holds significance in the pharmaceutical realm as a synthetic peptide used for managing excess abdominal fat accumulation in individuals with HIV-associated lipodystrophy. Functioning as a growth hormone-releasing hormone (GHRH) analog, tesamorelin stimulates the secretion of growth hormone, subsequently leading to an increase in insulin-like growth factor-1 (IGF-1) levels. This targeted approach addresses the abnormal fat distribution associated with lipodystrophy, particularly in the abdominal region. By promoting fat breakdown and reducing visceral adipose tissue, tesamorelin contributes to improved body composition and metabolic parameters. This pharmaceutical intervention underscores the nuanced strategies employed to enhance the quality of life for individuals facing HIV-related complications, showcasing tesamorelin’s role in addressing specific challenges in this patient population.

Current Research:Tesamorelin emerges as a promising treatment for lipodystrophy, a spectrum of fat redistribution and metabolic disorders often observed in people with HIV (PWH) undergoing antiretroviral therapy (ART). Lipodystrophy encompasses lipoatrophy, characterized by subcutaneous fat loss, and lipohypertrophy, marked by fat deposition in abdominal visceral adipose tissue (VAT) and other areas. While various factors contribute to lipodystrophy in PWH, including patient characteristics and ART duration, tesamorelin addresses the reduction of VAT, a crucial aspect of this condition.

Clinical studies have demonstrated tesamorelin’s efficacy in reducing VAT quantity and improving VAT quality in PWH. Notably, this synthetic growth hormone-releasing hormone (GHRH) has shown significant reductions in VAT at week 26, with sustained effects observed at week 52. Moreover, tesamorelin therapy has been well-tolerated without adverse effects on glucose metabolism. Post hoc analyses have identified predictors of response to tesamorelin, including baseline metabolic syndrome, elevated triglyceride levels, and racial factors.

Despite these advancements, questions remained regarding tesamorelin’s efficacy in patients with varying presentations of lipodystrophy, particularly those with excess dorsocervical fat. Recent data have addressed this concern, demonstrating tesamorelin’s effectiveness in reducing VAT regardless of dorsocervical fat deposition. Interestingly, while responders without dorsocervical fat exhibited additional reductions in subcutaneous adipose tissue (SAT) and limb fat, metabolic measurements remained equivalent between groups.

The study’s findings hold significant clinical implications, affirming tesamorelin as a viable treatment option for reducing VAT in patients with lipodystrophy, irrespective of dorsocervical lipohypertrophy. However, certain limitations, such as the exclusion of patients receiving placebo and the focus on VAT reduction alone, underscore the need for further research to comprehensively understand the impact of tesamorelin in patients with combined lipoatrophy and lipohypertrophy.

In conclusion, lipodystrophy poses considerable challenges to patients, and tesamorelin offers a valuable therapeutic intervention for addressing VAT accumulation in this population. As ongoing studies continue to elucidate tesamorelin’s role in managing lipodystrophy, clinicians can consider its use to alleviate the burden of this condition and improve patient outcomes.

Reference:Ma, I. L., & Stanley, T. L. (2023). Growth hormone and nonalcoholic fatty liver disease. Immunometabolism, 5(3), e00030.

Rahman, F., McLaughlin, T., Mesquita, P., Morin, J., Potvin, D., De Chantal, M., & Aberg, J. A. (2023). Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of Clinical and Translational Science, 7(1), e40.